Introduction {#Sec1}
============

Bispecific monoclonal antibodies (BsMAb) are uniquely engineered hetero-bifunctional macromolecules with two distinct binding specificities within a single molecule (Cao and Suresh [@CR6]; Suresh et al. [@CR69]). They represent the second generation of monoclonal antibodies, and although structurally bivalent, they are functionally univalent for binding each molecule. Typically, BsMAb have one paratope specific for a particular protein or an antigen and another paratope specific for a detection moiety such as an enzyme (Fig. [19.1](#Fig1){ref-type="fig"}). BsMAb can therefore function as versatile hetero-bifunctional cross-linkers. The binding of BsMAb to both molecules is dependent on the affinity of epitope--paratope interaction and is highly specific. BsMAb can be produced by three methods: (a) chemical conjugation involving chemical cross-linking (the original method for BsMAb production); (b) somatic hybridization involving hybridoma technology; and (c) genetic engineering involving recombinant DNA technology (Das and Suresh [@CR13]). Production of BsMAb by hybridoma technology involving bifunctional fusion (Fig. [19.2](#Fig2){ref-type="fig"}) of two different hybridomas that produce distinct monoclonal antibodies is more common compared to the other BsMAb production methods (Kohler and Milstein [@CR35]). BsMAb have been exploited for a variety of in vivo and in vitro applications ranging from diagnostics to therapeutics (Cao and Suresh [@CR6]). The use of BsMAb for different therapeutic applications and gene therapy is described in detail in earlier chapters. This chapter focuses only on the diagnostic applications of BsMAb.Fig. 19.1Diagrammatic representation of a bispecific antibody. One paratope of the Bispecific antibody is directed against a specific target antigen of a tumor, virus, bacteria, or a parasite. The second paratope of the Bispecific antibody is directed against an effector molecule, which may be a detection moiety (such as an enzyme), toxin, drug, liposome, radioisotope, cytokines or immune cells. The diagram is adapted from Cao and Suresh, Bioconjugate Chemistry, 1998 Fig. 19.2Schematic representation of bifunctional fusion. Two different monoclonal antibodies (MAb1 and MAb2) each directed against a specific epitope are fused to generate a bispecific monoclonal antibody (BsMAb)

BsMAb function as excellent diagnostic immunoprobes due to their intrinsic binding sites to any two molecules in a pre-determined order. They offer distinct advantages over other conventional probes used in diagnostic assays due to their monovalency for one antigen and simultaneous binding to a marker enzyme. One epitope of BsMAb is usually directed against a marker enzyme such as horse radish peroxidase (HRPO), alkaline phosphatase, or β-galactosidase, which enables signal generation in immunodiagnostic assays. BsMAb have been used in a number of diagnostic applications such as immunoassays, immunohistochemistry, and radio-immunodiagnosis (Kreutz and Suresh [@CR36]; Suresh [@CR67]; Suresh et al. [@CR68]). Their use in diagnostic assays has revolutionized the field of immunodiagnostics due to the higher sensitivity and reproducibility that can be achieved in the assays.

Advantages of Using BsMAb in Diagnostics {#Sec2}
========================================

The main advantage of using BsMAb in immunodiagnostics is that maximum specific activity and functional efficiency can be achieved since every antibody molecule is associated with a signal generating molecule (Kreutz and Suresh [@CR36]). In addition to making the diagnostic assays rapid, BsMAb enhance sensitivity and specificity of detection. They significantly reduce or even eliminate false positive reactions especially in assays such as ELISA. In the case of immunohistochemistry, the use of BsMAb leads to decreased background, fine and sharp morphological information, clear and distinct identification of immune reactive sides, and good resolution of ultrastructural details (Milstein and Cuello [@CR48]; Suresh et al. [@CR68]). Other advantages of using BsMAb in immunodiagnostic assays include improvement in signal to noise ratio and simplification of the assay procedure. They can easily be used as nanoprobes making ultrasensitive detection possible especially in the case of competitive immunoassays. In contrast to BsMAb, chemically conjugated monoclonal and polyclonal antibodies often exhibit higher background (Liu et al. [@CR43]).

Traditionally monoclonal antibodies have been employed in many immunodiagnostic assays. Typically, the use of monoclonal antibodies in diagnostic applications requires chemical manipulation of the antibody such as chemical cross-linking in order to conjugate the detection moiety (such as an enzyme or biotin) onto the antibody. Chemical cross-linking of detection moieties to antibodies has many disadvantages as outlined below (Kricka [@CR38]; Milstein and Cuello [@CR48]). (a) It is a random process where the combination ratio of the antibody and the conjugating chemical is not fixed, generally resulting in batch to batch variations in the detection reagent produced. (b) The size of the resultant conjugated antibodies is not uniform influencing their ability to penetrate, which is especially critical for immunohistochemical applications. (c) Inactivation of active site or binding site of the detection moiety or the antibody and/or aggregation may occur during chemical conjugation. (d) Covalent linkages occur between the detection moiety and the antibody, which is not very preferable for in vivo diagnostic applications. (e) The antibodies produced often have low specific activity and decreased shelf life. The above factors have a significant impact on the performance of the conjugated monoclonal antibodies and therefore the reproducibility of the immunodiagnostic assay method. In contrast, the use of BsMAb completely eliminates the need for chemical conjugation of the antibody with the detection moiety. The bispecific nature of BsMAb ensures that the combination ratio of the antibody and the detection moiety is always 1:1. Further, since BsMAb are generally already tagged with the detection enzyme during the purification step, extra steps of enzyme addition and subsequent washing can be avoided during the immunoassay. BsMAb function as uniform, homogenous immunoconjugates with reproducible high specific activity and therefore serve as an excellent alternative to chemically conjugated monoclonal antibodies.

BsMAb are extremely versatile and function as robust immunoconjugates in the assay. They can be used in a variety of immunodiagnostic assays that are designed in multiple formats including the conventional format such as the microtitre plate assay and as well newer formats such as swab, strip, or filter disk assays. In the newer formats the end point of the assay can be read out visually without the need of any instrument, which makes the immunoassay extremely convenient for use as a point of care detection test in diverse health care settings.

BsMAb for Diagnosis of Infectious Diseases {#Sec3}
==========================================

One of the major challenges for the global health care system is to control the spread of infectious diseases, which cause 9.5 million deaths annually (WHO ([@CR75]), World Health Organization report). Diagnosis of a disease at its early stage is of paramount importance in combating both its progression and spread in the community. In order to develop effective diagnostic immunoassays for various infectious diseases, the high specificity of antigen--antibody interaction can be exploited. Due to their unique characteristics, BsMAb are extremely useful for developing simple, rapid, and point of care immunodiagnostic assays for detection of infective particles (specific antigen of the infective agent). The following sections describe some examples for the use of BsMAb in the diagnosis of infectious diseases caused by both bacteria and viruses.

Diagnosis of Bacterial Infections {#Sec4}
---------------------------------

### *Mycobacterium tuberculosis* {#Sec5}

According to the World Health Organization (WHO) about 1.3 million deaths were due to tuberculosis (TB) alone in the year 2008 (WHO-TB ([@CR76]), World health organization report on TB). Lack of early detection of infected individuals has resulted in the rapid spread of this disease to different parts of the world. The problem is further compounded due to co-infection with human immunodeficiency virus (HIV) that has led to a steep increase in morbidity and mortality. In fact, TB has now become the leading cause of death for HIV-infected patients (WHO-TB ([@CR76]), World Health Organisation report on TB). TB is caused by the bacterium *Mycobacterium tuberculosis*, which is highly resilient and rampant worldwide. The current diagnosis for *M. tuberculosis* mainly relies on the result of sputum smear microscopy (SSM) and bacterial culture method, both of which are not useful for early stage detection. SSM is not very sensitive and can only detect if the bacterial load is above 10^4^/ml of sputum. Moreover, it is often difficult to collect sputum samples from elderly and pediatric populations who are especially vulnerable to *M. tuberculosis* infection due to their weak immune system. Bacterial culture method, which is still regarded as the gold standard for detecting *M. tuberculosis* takes about 7--10 days to provide results and also requires dedicated culture facilities. In the majority of TB cases, due to the above problems, detection is often performed based on clinical symptoms and results of chest radiograms. However, none of the above methods are specific because many other pulmonary diseases also show similar symptoms and chest radiograms. As a result of this delayed and faulty diagnosis system, patients are often treated incorrectly and in most cases this partly contributes to bacterial evolution towards multi-drug resistant (MDR) and extremely drug resistant (XDR) strains of *M. tuberculosis*.

Recently, sophisticated molecular assays such as interferon gamma release assay (IGRA) and nucleic acid amplification (NAA) assay have become available; however, their performance is also questionable (Campos et al. [@CR5]; Lalvani and Millington [@CR39]; Madariaga et al. [@CR44]). These molecular assays are moreover difficult to perform in resource-constrained countries due to their high cost and requirement of technical sophistication. Currently there is no simple, rapid, and inexpensive point of care immunodiagnostic assay available for the detection of *M. tuberculosis*. Our laboratory therefore has developed a novel and highly sensitive immunodiagnostic assay for the detection of *M. tuberculosis* using BsMAb (Sarkar and Suresh 2010, University of Alberta, Unpublished data). Only a general outline of the developed BsMAb-based immunodiagnostic assay is described here. To design the immunoassay in either strip or swab format, any specific *M. tuberculosis* antigen can be used to generate BsMAb. The unraveling of the complete genome sequence of *M. tuberculosis* (Cole et al. [@CR12]) has made it easier to identify antigens that are highly specific to the bacteria and not other related members of mycobacteria. Some of the important *M. tuberculosis* antigens (Palma-Nicolas and Bocanegra-Garcia [@CR51]) that could be possible candidates for BsMAb generation are mentioned in Table [19.1](#Tab1){ref-type="table"}.Table 19.1Important *M. tuberculosis* antigensProtein antigensESAT6, CFP10, Mtb48, Mtb81, and 16 kDa-, 30 kDa- and 38 kDa-Protein antigensLipid antigensDiacyl trehalose, triacyl trehalose, trehalose dimycolate and sulfolipidsPolysaccharide antigensLipoarabinomannan and arabinomannan

The chosen *M. tuberculosis* antigen is used to first generate a monoclonal antibody and in the subsequent step the hybridoma secreting the monoclonal antibody is fused with another hybridoma secreting monoclonal antibody against any of the detection enzymes like HRPO or alkaline phosphatase to obtain a hybrid-hybridoma or quadroma producing the desirable BsMAb (Kreutz et al. [@CR37]; Suresh et al. [@CR69]). After isolating a stable clone expressing the BsMAb, it is expanded in a bioreactor and subsequently the BsMAb is purified using affinity chromatography. Our laboratory has designed a novel purification process to isolate BsMAb in which one of the fusion monoclonal antibody partners is directed against HRPO (Bhatnagar et al. [@CR3]). The process allows high efficiency purification of the BsMAb using *m-*aminophenylboronic acid agarose column along with HRPO tagging. The general format of the immunoassay involves coating a solid phase (swab or strip) with the *M. tuberculosis* antigen-specific monoclonal antibody and then blocking any unbound sites using a suitable buffer. The coated and blocked swab/strip is incubated with the clinical specimen collected from the patient. The *M. tuberculosis* antigen present in the sample would then specifically bind to the monoclonal antibody and other non-specific unbound materials are washed off, after which, the purified BsMAb is used as the detection antibody. As one arm of BsMAb can recognize the antigen, it would bind to the antigen forming a sandwich. Given that BsMAb is already tagged with HRPO, addition of the enzyme substrate 3, 3′, 5, 5′-tetramethylbenzidine (TMB) results in the formation of blue color that can easily be identified. A schematic of the general assay format is shown in Fig. [19.3](#Fig3){ref-type="fig"}.Fig. 19.3General assay format for BsMAb-based immunoassay. The capture monoclonal antibody (MAb) is first immobilized onto a solid phase. This antibody binds to the respective specific antigen present in the test sample. Upon addition of the corresponding Bispecific monoclonal antibody (bsMAb), one arm of the bsMAb binds to the specific antigen while the other arm bound to HRPO converts the subsequently added TMB substrate to a blue colored product that can be easily detected

The BsMAb-based immunodiagnostic assay for the detection of *M. tuberculosis* infection has several distinct advantages. The assay is highly specific, sensitive and at the same time easy to perform since it does not require any technical expertise. In addition, results of the assay can be obtained within few hours of sample collection and also the end point can be read out visually. Furthermore, the design of the assay makes it inexpensive so that the test can easily be performed in resource-constrained settings.

### *Escherichia coli* O157:H7 {#Sec6}

*E. coli* O157:H7 belongs to the group of Verocytotoxin or Shiga toxin producing *E. coli* that has surfaced as an important food- and water-borne pathogen worldwide (Fraser et al. [@CR16]; Law [@CR41]). It causes non-bloody or bloody diarrhea (hemorrhagic colitis) and hemolytic uremic syndrome characterized by hemolytic anemia, thrombocytopenia, and acute renal failure (Griffin and Tauxe [@CR20]). *E. coli* O157:H7 is therefore classified as enterohemorrhagic *E. coli* (EHEC); it is reported to cause about 73,000 cases of infections per year in the United States alone (Mead et al. [@CR47]). Several outbreaks of *E. coli* O157:H7 infection have been associated with recreational and municipal drinking water in North America, United Kingdom, and Japan (Bopp et al. [@CR4]; Hrudey et al. [@CR27]). Current methods to detect *E. coli* O157:H7 in water and food are traditional enrichment and plating on Sorbitol MacConkey agar and Rainbow agar selective media, Polymerase chain reaction (PCR), and other immunological methods (Bennett et al. [@CR2]; Manafi and Kremsmaier [@CR45]). The main drawbacks of these methods include time requirement (24--48 h for culture), difficulty in isolating DNA from sample (for PCR) and low sensitivity. It is important to note that low colony forming units (CFU) of *E. coli* O157:H7 present in contaminated food and water is generally sufficient to cause a severe infection, therefore having a sensitive method for detection during investigations of outbreaks is vital.

A highly sensitive BsMAb-based immunodetection assay was developed by our laboratory for the detection of *E. coli* O157:H7 in water samples (Guttikonda et al. [@CR23]). *E. coli* O157:H7 whole bacteria and *E. coli* O157:H7 lipopolysaccharide (LPS) were used to first generate a monoclonal antibody, the hybridoma of which, was fused with anti-HRPO secreting monoclonal antibody hybridoma (Kreutz et al. [@CR37]; Suresh et al. [@CR69]) to generate a quadroma producing BsMAb specific for both *E. coli* O157 and HRPO. The BsMAb was subsequently purified using benzhydroxamicacid agarose column (Husereau and Suresh [@CR28]) and used in sandwich ELISA immunoassay. The anti-*E. coli* O157:H7 monoclonal antibody was used as the capture antibody to bind the bacteria from samples and the BsMAb was used as the detection antibody (Guttikonda et al. [@CR23]). Refer to Fig. [19.3](#Fig3){ref-type="fig"} for the general assay format. The detection limits of the assay were found to be 100 and 750 CFU/ml of sample for tap water and lake water, respectively. The immunoassay was further adapted to an immunofilter assay format to suit public health applications such as in water testing laboratories (Guttikonda et al. [@CR23]). As low as 50 CFU of *E. coli* O157:H7/100 ml water were detected indicating that the assay is highly sensitive. Moreover the assay is highly specific since it did not detect a 500-fold excess of other bacterial strains such as *Salmonella*, *Pseudomonas*, and as well non-O157:H7 and non-pathogenic *E. coli*. A higher signal to noise ratio and a clean background was achieved in the assay since BsMAb served as a high specific activity probe. The BsMAb-based immunodetection assay therefore functions as a robust, ultrasensitive, and quick method for the detection of *E. coli* O157:H7. It has distinct advantages as it eliminates the amplification step required by other current assays and could easily be developed as a routine screening assay for detection of *E. coli* O157:H7 in water bodies especially in developing countries.

### *Bordetella pertussis* {#Sec7}

Whooping cough or pertussis caused by the bacterium *Bordetella pertussis* has become a major health concern in recent years especially among the adolescent age group (CDCP [@CR10], Centers for Disease Control and Prevention). Early and accurate diagnosis is critical in order to prevent the spread of infection and also ensure proper treatment of the affected individual. Conventional diagnosis of *B. pertussis* infection involves identification of the bacterium from culture of clinical nasopharyngeal aspirate samples, which generally takes about 3--7 days (Josephs [@CR30]). Moreover, successful isolation and characterization is in turn dependent on several other factors such as proper specimen collection from the respiratory tract, storage, and culture conditions (Gustafsson et al. [@CR22]). Another method for detection of *B. pertussis* involves the use of direct fluorescent-antibody assay that employs a fluorescence-labeled monoclonal antibody directed against a predominant antigenic LPS molecule present on the outer membrane of the bacterium (McNicol et al. [@CR46]; Peppler [@CR54]). Although detection of LPS is a good strategy, the assay is not sensitive and is also not easy to perform (Tilley et al. [@CR72]).

Our laboratory therefore developed a highly sensitive and simple BsMAb-based immunodiagnostic assay for the detection of whole *B. pertussis* and soluble *B. pertussis* LPS (Tang et al. [@CR71]). The assay is useful not only for analyzing clinical samples but also for immunochemical structural studies and serological characterization of *B. pertussis* LPS. The anti-*B. pertussis* LPS monoclonal antibody secreting hybridoma and the anti-HRPO monoclonal antibody secreting hybridoma were fused to generate a quadroma that produces BsMAb specific to both *B. pertussis* LPS and HRPO. BsMAb was subsequently purified by affinity chromatography using benzhydroxamicacid agarose column (Husereau and Suresh [@CR28]) and used in a homosandwich ELISA immunoassay. Heat-killed *B. pertussis* BP347 by itself or spiked into nasopharyngeal aspirates was first bound by the anti-LPS specific monoclonal antibody, and then the BsMAb was added as the detection antibody (Tang et al. [@CR71]). Refer to Fig. [19.3](#Fig3){ref-type="fig"} for the general assay format. The assay showed high sensitivity with a practical lower limit of detection of *\~*5 CFU; the extrapolated theoretical lower limit of detection was found to be one bacterium by using the mean + 2 standard deviations of 20 control assays without *B. pertussis*. Interestingly, binding of *B. pertussis* to the anti-*B. pertussis* LPS monoclonal antibody-coated solid phase was found to be irreversible despite extensive washing suggesting a unique molecular velcro effect (Tang et al. [@CR71]). The use of BsMAb in the immunoassay allowed ultrasensitive detection of *B. pertussis* since it avidly captured multiple exposed LPS molecules on the bacterial surface.

The BsMAb-based immunodiagnostic assay was adapted to an immunoswab format to facilitate easy, rapid, and point of care detection of *B. pertussis* in a primary health care setting. The sensitivity of detection was high since as few as ten bacteria could be detected compared to the controls (Tang et al. [@CR71]). The BsMAb-based assay has unique advantages in being highly sensitive and easy to perform. It therefore facilitates early detection of *B. pertussis* infection and accurate monitoring of outbreaks of whooping cough.

Diagnosis of Viral Infections {#Sec8}
-----------------------------

### Severe Acute Respiratory Syndrome Coronavirus {#Sec9}

Severe acute respiratory syndrome (SARS) epidemic affected more than 8,000 people worldwide spreading over 30 countries across 5 continents in the 2002--2003 outbreak (Drosten et al. [@CR15]; Peiris et al. [@CR52]; Poon et al. [@CR56]). This highly contagious infection claimed over 900 lives in a short period of time with a fatality rate of 9.6%, emerging as a huge global threat to human health. SARS Coronavirus (SARS-CoV) is the etiological agent of SARS, which is believed to have transmitted from wild animals to the human population (Guan et al. [@CR21]; Wang et al. [@CR74]). According to WHO, the absence of a rapid screening test delayed the diagnosis of suspected cases of SARS and resulted in the spread of the disease worldwide. Current methods for the confirmation of SARS infection include detection of viral RNA by reverse transcription-PCR (Jiang et al. [@CR29]; Poon et al. [@CR55]; Yam et al. [@CR78]), detection of SARS-CoV antibodies in body fluids using indirect fluorescence assay (Chan et al. [@CR11]), and isolation of SARS-CoV from clinical samples (Keyaerts et al. [@CR32]; Yamashita et al. [@CR79]). Since viral culture is a time consuming, tedious, and insensitive method, PCR and antibody detection methods are widely used; however, these two methods are expensive, laborious, and require technical expertise (Wu et al. [@CR77]). A simple, rapid and inexpensive diagnostic test for the specific and early detection of SARS-CoV is therefore extremely important to limit the spread of infection and for proper risk management in the case of a future global outbreak especially since SARS has high rates of transmission and mortality.

Our laboratory has developed a highly sensitive, rapid, and simple BsMAb-based immunoswab assay for early detection of SARS-CoV (Kammila et al. [@CR31]). The assay is designed to detect the most abundant and conserved viral antigen nucleocapsid protein NP (Di et al. [@CR14]; Hiscox et al. [@CR26]; Lau et al. [@CR40]; Rota et al. [@CR59]; Suresh et al. [@CR70]) because its presence in different body fluids (serum, urine, nasopharyngeal aspirate, throat wash samples, and saliva) is suggestive of current infection. Three different monoclonal antibodies that recognize different epitopes on NP antigen and the anti-HRPO monoclonal antibody were employed to generate the BsMAb using hybrid-hybridoma technology. The obtained anti-SARS-CoV × anti-HRPO BsMAb was then purified by a novel, dual sequential affinity chromatography method (Protein-G column followed by *m-*aminophenyleboronic acid agarose column), which was developed by our laboratory (Bhatnagar et al. [@CR3]). In the immunoswab assay, easy-to-use swabs were first coated with anti-SARS-CoV monoclonal antibody to capture NP in the test sample followed by detection with BsMAb (Kammila et al. [@CR31]). Refer to Fig. [19.3](#Fig3){ref-type="fig"} for the general assay format. The assay successfully detected SARS-CoV NP antigen spiked in different matrices such as saline, serum, and pig nasopharyngeal aspirate with high sensitivity. Pig nasopharyngeal aspirate was used as surrogate to human samples to test the ability of the immunoswab assay to detect low concentrations of NP antigen. The immunoswab assay showed NP detection limits of 10 pg/mL (1 pg/swab) in saline, 20--200 pg/mL (1--10 pg/swab) in pig nasopharyngeal aspirate and 500 pg/mL (25 pg/swab) in rabbit serum. Further, the sensitivity of NP detection was high in BsMAb-based assay compared to a parallel MAb-based assay (20 pg/mL vs. 200 pg/mL in saline; 20--200 pg/mL vs. 200 pg/mL in pig nasopharyngeal aspirate) indicating that the BsMAb-based immunoassay works better than its MAb-based counterpart. Furthermore to determine the robustness of the assay, swabs pre-coated with capture antibody were tested after storage for 2-, 6-, 10-, and 14-week time periods under different conditions (Kammila et al. [@CR31]). The BsMAb-based immunoswabs showed good sensitivity for NP detection even on week 14 at 200 pg/mL (4°C storage) and 500 pg/mL (RT and −20°C storage) indicating a good shelf-life for the immunoswabs.

The immunoswab format has potential advantages particularly in clinical, rural, and primary healthcare settings such as ease of use, early phase detection, and in limiting the spread of infection. It is also extremely useful for SARS screening at all ports of mass human entry (airports, seaports, bus, train, and border stations). Interestingly, the time required to perform the assay was approximately 45 min, which make it a rapid test for SARS diagnosis (Kammila et al. [@CR31]). The assay can easily be used to screen numerous suspected individuals within a short period of time during a future SARS outbreak given the relative ease of accessing nasopharyngeal aspirate with no invasive procedures. The BsMAb-based immunoswab detection of SARS-CoV NP antigen therefore serves as a simple point of care diagnostic test compared to other current methods (Di et al. [@CR14]) and is also highly sensitive, inexpensive, and requires minimally trained personnel.

### Dengue Virus {#Sec10}

Dengue fever caused by Dengue virus is the most prevalent mosquito-borne viral infection in the world as more than 100 million cases are reported each year predominantly in the tropical and sub-tropical regions (Hemungkorn et al. [@CR25]). Dengue virus belongs to the Flaviviridae family and four different serotypes (DENV1, DENV2, DENV3, and DENV4) have been identified so far. In humans, dengue viral infection causes a spectrum of diseases ranging from asymptomatic infection to severe hemorrhagic fever ultimately resulting in death (Hemungkorn et al. [@CR25]). Diagnosis of dengue infection based on clinical symptoms cannot be deemed reliable, and therefore detection of the specific virus, viral antigen, genomic sequence, and/or antibodies is absolutely essential to confirm infection. Current methods to diagnose dengue infection include virus isolation, and other serological and molecular techniques that employ monoclonal or polyclonal antibodies labeled with an enzymatic or fluorometric marker (Shu and Huang [@CR64]). These methods are less reliable, and moreover those that identify the virus or the viral genome are expensive and require specialized laboratories. It is important to diagnose an on-going or recent infection during the acute or early convalescent stages in order to facilitate better treatment, and ensure effective etiological investigation and disease control (Halstead [@CR24]). Currently there is no sensitive, simple, and inexpensive diagnostic assay available for the detection of dengue virus infection at the acute or early stages.

Our laboratory has developed a novel, highly sensitive immunodiagnostic assay for the detection of Dengue virus using BsMAb (Ganguly and Suresh 2010, University of Alberta, Unpublished data). Only a general outline of the developed BsMAb-based immunodiagnostic assay is described here. To design the immunoassay, any specific Dengue virus antigen can be used to generate BsMAb that could be employed in a simple strip or swab assay format. The selected Dengue virus antigen is used to first generate a monoclonal antibody and in the subsequent step, the hybridoma secreting the monoclonal antibody is fused with another hybridoma secreting monoclonal antibody specific for HRPO to produce a quadroma producing the desired BsMAb. The BsMAb is subsequently purified by affinity chromatography using *m-*aminophenylboronic acid agarose column (Bhatnagar et al. [@CR3]). The general format of the immunodiagnostic assay involves coating Dengue virus antigen-specific monoclonal antibody as the capture antibody on calcium alginate tipped swabs with aluminum/or plastic shafts as per previously published protocol (Tang et al. [@CR71]). The swab is then blocked and later incubated with the specific antigen spiked in serum, after which, the purified BsMAb is used as the detection antibody. Addition of the HRPO substrate, TMB, results in the formation of blue color that can be identified visually (Refer to Fig. [19.3](#Fig3){ref-type="fig"} for the general assay format).

The BsMAb-based immunodiagnostic assay for Dengue virus detection has several advantages. The assay is highly specific and easy to perform since it does not require any technical expertise or sophisticated instruments. In addition, the design of the assay makes it rapid and convenient as a point of care detection tool apt for use in primary health care settings and remote villages. These features make the assay very suitable for early detection of dengue infection and thereby control its spread in the community.

BsMAb for Diagnosis of Cancer {#Sec11}
=============================

In addition to their un-controlled growth and aberrant cellular physiology, cancerous cells are often characterized by the presence of over-expressed biochemical molecules such as glycoproteins that are present on the cell surface and later shed into body fluids. Such over-expressed tumor-specific antigens have been exploited as markers to enable diagnosis, and in conjunction with a battery of clinical methods can also be of prognostic relevance. Based on specific tumor-associated antigens (TAA), BsMAb can be generated for use in cancer diagnostics (Songsivilai and Lachmann [@CR65]; Souriau and Hudson [@CR66]). Such BsMAb would bind to the corresponding cancer-specific antigen in the test sample and provide an easy read-out regarding the presence of a specific type of cancer. It is becoming more and more apparent that early and confirmative diagnosis of cancer is critical for the control and cure of the disease. Due to their distinct characteristics of being powerful immunoprobes, BsMAb are extremely valuable in developing simple, rapid, and highly sensitive immunodiagnostic assays that can be used for the detection of various types of cancer. The following sections describe the use of BsMAb in detection and diagnostic imaging of cancer.

Prostate Cancer {#Sec12}
---------------

Prostate cancer is most common in men and is responsible for more deaths than any other cancer, except for lung cancer (NCI [@CR49], National Cancer Institute Statistics). About 218,890 new cases of prostate cancer were diagnosed in the United States alone during 2007. It is expected that 1 out of 6 men will be diagnosed with prostate cancer during their lifetime; a little over 1.8 million men in the United States are survivors of prostate cancer (NCI [@CR49], National Cancer Institute Statistics). Prostate-specific antigen (PSA) is a useful tumor-associated marker present in the serum that is widely used for screening and monitoring progression of prostate cancer (Caplan and Kratz [@CR7]). There are several different assays currently available for the measurement of PSA, most of which involve the use of labeled monoclonal or polyclonal antibodies (Armbruster [@CR1]; Cattini et al. [@CR9]; Khosravi et al. [@CR33]; Klee et al. [@CR34]; Leinonen et al. [@CR42]; Oesterling et al. [@CR50]; Vihko et al. [@CR73]; Yu and Diamandis [@CR80]). These assays are technically complex, time consuming, and have lower sensitivity.

Our laboratory therefore developed a novel, highly sensitive, and rapid BsMAb-based immunoassay for the measurement of PSA (Kreutz and Suresh [@CR36]). The anti-PSA monoclonal antibody secreting hybridoma was fused with anti-HRPO secreting hybridoma using the hybrid-hybridoma technology to generate a quadroma producing the anti-PSA × anti-HRPO BsMAb. The BsMAb was then purified by ammonium sulfate precipitation, anion exchange, and affinity chromatography, after which, it was used in the PSA immunoassay. The anti-PSA monoclonal antibody was used as the capture antibody and the BsMAb was used as the detection antibody to measure PSA levels in the test samples in a 20-min single-step assay (Fig. [19.4](#Fig4){ref-type="fig"}). The assay had high analytical sensitivity even with a short substrate incubation time; the detection limit was comparable to most commercially available assays requiring longer incubation times (Kreutz and Suresh [@CR36]). With TMB as the enzyme substrate, a sensitivity of 0.028 mg/L was achieved for 5-min substrate incubation in comparison to the commercially available Hybritech Tandem-EIA^R^ PSA assay that had a detection limit of 0.1 mg/L for 30-min substrate incubation. The developed assay was further evaluated using 138 clinical samples and results were found to correlate with those obtained by an automated Hybritech enzyme PSA immunoassay (Kreutz and Suresh [@CR36]). Overall, the BsMAb-based immunoassay for PSA measurement has rapid kinetics and an excellent detection limit, which makes it a good candidate for use in the development of next-generation automated immunoassays and for rapid screening in health clinics.Fig. 19.4Schematic representation of antibody complex formed during BsMAb-based immunoassay for PSA detection. PSA in the test sample is bound first by the capture monoclonal antibody and then by BsMAb detection antibody tagged to peroxidase (HRPO) to form an antibody sandwich complex. The diagram is adapted from Kreutz and Suresh, Clinical Chemistry, 1997

Cancer Diagnostic Imaging {#Sec13}
-------------------------

Molecular imaging has transformed the field of cancer diagnosis with its superior ability to identify and localize cancer based on distinct molecular and functional characteristics of cancerous tissue. ^18^F-flurodeoxyglucose (^18^F-FDG)-based imaging using positron emission tomography (PET) or computed tomography (CT) has become popular for the detection and assessment of different types of tumors. Various specific monoclonal antibodies directed against different cancer antigens have also been employed; however, the sensitivity of these techniques is low compared to ^18^F-FDG-PET/CT. In theory, monoclonal antibodies should have been more ideal imaging candidates owing to their higher degree of specificity for tumor antigens and their ability to discriminate between tumor and inflammation. However, the high molecular weight of the radiolabeled monoclonal antibodies limits tumor uptake and causes insufficient clearance from surrounding tissues resulting in low contrast during imaging. The size also interferes with the ability of these molecules to extravasate from the vascular channels into the extravascular space thus leading to slow accretion of radiolabeled antibodies in tumors (typically 1--3 days to achieve maximum tumor uptake). While tumor uptake of radiolabeled monoclonal antibodies may reach between 10 and 30% of injected dose per gram of tumor in mouse xenograft models, there may only be an accretion of \<0.1% injected dose per gram of tumor in humans owing to a larger vascular and extravascular volume of distribution. Although several antibody modifications have been made along with changes to the radionuclide moiety in order to obtain better signal to noise ratios and avoid non-specific tissue uptake by liver, kidneys, and bone marrow, none of them have yielded expected results.

In recent times, BsMAb have proven to be more useful in cancer diagnostic imaging especially using the "pre-targeting" strategy (Cardillo et al. [@CR8]; Gold et al. [@CR17]; Goldenberg et al. [@CR18], [@CR19]; Rearden et al. [@CR57], [@CR58]; Sharkey et al. [@CR63]). This strategy aims to deliver high tumor accretion, eliminate background noise due to untargeted radioactivity from blood and normal tissues, and reduce unintended toxicity. It relies on BsMAb's ability to effect tumor localization of the subsequently administered radiolabeled effector molecule. Targeting is achieved with BsMAb that binds to a target antigen with one arm and to a radiometal-chelate or hapten peptide complex (effector molecule) with the other arm. Animal model experiments have revealed an equivalent tumor uptake of BsMAb compared to radiolabeled antibodies and maximum accretion within minutes rather than several hours or days. Even the radionuclide was cleared very rapidly from the body, with more than 80% of the product eliminated in the urine within a few hours, allowing tumor/blood and tissue ratios to often be ≥10:1 within 1 h of the radionuclide administration. Tissue retention of the radiolabeled effector molecule was also found to be very low, even in the kidneys and liver that very often show elevated uptake of directly radiolabeled antibodies unless radioiodine is used. The use of BsMAb has significantly enhanced the imaging utility of pre-targeting procedures as compared to using directly radiolabeled antibodies. The de-coupling of the effector molecule from the pre-targeting agent is central to all the variations on this theme that has resulted in enhanced imaging of tumors.

BsMAb can be used in a simple two-step pre-targeting approach without the need for any clearing step or additional agents. Two-step procedures generally involve injection of the pre-targeting agent such as BsMAb and waiting for a day or two before all of the unbound fractions are drained off from the body's circulation by excretion through liver or kidneys (BsMAb are easily cleared from the blood within a day). This is followed by administration of the radiolabeled effector molecule, which would only bind to a specific arm on the pre-targeted BsMAb at the tumor site. Patients would therefore be able to receive BsMAb injection by their oncologist, return a few days later and receive the radiolabeled product in a nuclear medicine facility such that imaging can be accomplished on the same day. Although it may take a few days before an image can be achieved using a pre-targeting approach, experienced investigators and preclinical data have suggested that the images would be superior in terms of specificity, sensitivity, signal intensity, and have minimal background compared to those obtained using radiolabeled monoclonal antibodies. In many cases, BsMAb-based pre-targeting approach has out-performed the results generated by clinically approved radiolabeled monoclonal antibodies, especially in imaging small tumors in colorectal and colonic cancer (Sharkey et al. [@CR62]). In addition to giving better tumor/blood ratios, superior tumor uptake, enhanced tumor/non tumor ratios, the pre-targeted strategy retained tumor-specific signal intensity even 1 day post-injection of the radioactive effector molecule thus providing a 15-fold increase in signal strength at the tumor site. BsMAb are currently being exploited for imaging many CEA-expressing tumors, MUC-1-expressing pancreatic cancer, and CD20-expressing non-Hodgkin's lymphoma (Peltier et al. [@CR53]; Schuhmacher et al. [@CR60], [@CR61]).

BsMAb-based pre-targeting techniques for diagnostic imaging of cancers have taken nuclear imaging to a whole new level and are beginning to complement the present-day gold standard of ^18^F-FDG-PET. BsMAb are being further engineered to achieve optimal molecular weight and charge for better tumor uptake, rapid blood clearance, higher valency, improved affinity to TAA, enhanced signal intensity, and greater flexibility for binding to a variety of hapten-peptides carrying different radio-isotopes. Improvements in the methods used for the production of BsMAb by "Dock and Lock" molecular engineering strategies and their application in furthering pre-targeting applications in tumor imaging and therapy is described in Chap. 10.1007/978-3-642-20910-9_12. Given that highly specific and sensitive images are possible with BsMAb pre-targeting in both the experimental and clinical set up, it is evident that BsMAb-based cancer diagnostic imaging is very promising.

Conclusion {#Sec14}
==========

The use of BsMAb in immunodiagnostic assays has resulted in the development of next generation immunoassays that are highly sensitive, rapid, simple, and cost-effective. The specificity of the assays approaches the theoretical limit of immunodetection making them ultrasensitive. Importantly, these assays are invaluable as a point of care diagnostic tool. Such assays are of immense value especially in some resource-constrained countries to combat the spread of diseases. Rapid detection of communicable diseases has huge impact on the current global health scenario where an infectious disease can make quick transition from an epidemic to a pandemic like the recent outbreak of swine flu. Most of the current diagnostic assays measure specific antibodies to bacterial or viral antigens and therefore may report a previous infection since antibodies circulate in the blood 6 months post-infection. Such assays rarely detect infection at initial stages making early intervention almost impossible. In contrast, BsMAb-based diagnostics measure specific bacterial or viral antigens rather than the antibodies and therefore accurately reflect active diseased state and make early-stage detection possible.

In the coming years, BsMAb will prove valuable for use in diagnosis of different types of cancer. Since BsMAb-based cancer diagnosis has many advantages and is highly sensitive it will be useful not only for early detection of cancer but also convenient for monitoring the progression of the diseased state and assessing response to treatment. Given the immense potential of BsMAb as excellent immunoprobes, there are efforts to engineer newer forms of these antibodies with significantly improved binding specificity and avidity. BsMAb await a plethora of novel applications in the field of diagnostics.
